Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund

Q&A on the AMR Fund with Thomas Cueni, director general of IFPMA

The International Federation of Pharmaceutical Manufacturers & Associations has spearheaded the creation of the AMR Action Fund, which has lined up about $1 billion from over 20 pharmas to invest in biotechs developing solutions to antimicrobial resistance.

BioCentury spoke with IFPMA Director General Thomas Cueni, who called the fund a bridge that will carry a few products from Phase II to approval. Cueni noted that other “push” mechanisms are in place for antibiotic development, including the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the REPAIR Impact Fund, which was established by Novo Holdings, but these initiatives focus on early-stage development.

Cueni stressed that the fund is only part of

Read the full 1093 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers